Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for Long COVID-19
NCT05719012Phase 2Withdrawn
- Sponsor
- Shanghai East Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of human umbilical cord mesenchymal stem cells in post acute COVID-19 syndrome, sponsored by Shanghai East Hospital. Planned start Apr 2023; status: withdrawn.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT05719012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05719012.